Cholestasis arises when the delicate plumbing of the liver fails. Bile, a detergent-like fluid produced by hepatocytes to carry away cholesterol, toxins, and metabolic waste, must be exported through a series of specialized transporter proteins embedded in the canalicular membrane of liver cells. When that export system breaks down, bile acids back up inside hepatocytes, where their detergent properties become a weapon against the very cells that produce them. The result is oxidative stress, inflammatory signaling, programmed cell death, and eventually fibrosis. Among the transporters involved, the bile salt export pump, known as BSEP, occupies a central position. It is the primary efflux pump for conjugated bile acids, and its dysfunction is widely regarded as a key initiating event in cholestatic liver damage, whether the cause is a genetic mutation, a drug side effect, or a chemical insult.

To model this injury experimentally, the researchers turned to alpha-naphthyl isothiocyanate, or ANIT, a compound long used to induce intrahepatic cholestasis in laboratory animals. ANIT damages the biliary epithelium and disrupts canalicular transport, producing a cascade of biochemical and histological changes that closely mirror human cholestatic disease. Sixty male Sprague Dawley rats were randomly assigned to five experimental groups: a healthy control group, a group receiving ANIT alone, two groups pretreated with selenium at doses of 0.5 and 1 milligram per kilogram of body weight before ANIT exposure, and a group receiving selenium alone to assess the element’s intrinsic safety profile at these doses.

The damage inflicted by ANIT was comprehensive. The researchers documented marked suppression of BSEP, along with two other critical transporters, MRP2 and NTCP, which together coordinate the import and export of bile acids and their metabolites across hepatocyte membranes. Simultaneously, the expression of genes governing bile acid synthesis and detoxification, including CYP7A1, UGT1A1, and the nuclear receptor FXR that orchestrates much of bile acid homeostasis, was thrown into disarray. These molecular disruptions translated into measurable clinical harm: serum markers of cholestasis and liver injury climbed, oxidative stress intensified, inflammatory signaling pathways were activated, and hepatocytes underwent increased apoptosis. Under the microscope, liver tissue showed pronounced histopathological injury and early fibrotic changes, confirming that the model had faithfully reproduced the destructive arc of cholestatic disease.

Selenium pretreatment changed that picture dramatically, but only at the higher dose. At 1 milligram per kilogram, the element significantly attenuated ANIT-induced damage across nearly all biochemical, molecular, and histopathological endpoints examined. Bile acid transporter expression was preserved, the balance of bile acid synthesis and detoxification was rebalanced, and the downstream consequences of transporter failure, including oxidative damage, inflammation, and cell death, were substantially blunted. By contrast, the lower dose of 0.5 milligrams per kilogram produced only partial improvements, and for several key parameters, including serum ALT, AST, GGT, and bilirubin levels as well as oxidative and inflammatory markers, the differences relative to the ANIT-only group did not reach statistical significance. This dose-dependence is a critical finding, suggesting that selenium’s protective window in this context is narrower than a simple more-is-better assumption might imply.

Delving into the signaling mechanisms, the team found that the protective effect was accompanied by activation of the NRF2/HO-1 axis, one of the cell’s master antioxidant defense systems, and by stimulation of Sirt1, a nutrient-sensing deacetylase with well-established roles in cellular stress resistance and metabolic regulation. At the same time, selenium suppressed inflammatory signaling mediated by TLR4 and the transcription factor NF-κB, a pathway that ANIT exposure had strongly activated. Perhaps most intriguingly, the researchers observed reactivation of PI3K/AKT/mTOR-dependent pro-survival signaling, suggesting that selenium did not merely mop up reactive oxygen species but actively shifted hepatocytes from a death-oriented to a survival-oriented signaling state. Together, these pathways form a coherent mechanistic narrative in which selenium stabilizes the liver’s bile acid export machinery while simultaneously fortifying its defenses against the oxidative, inflammatory, and apoptotic fallout of cholestatic stress.

The study also incorporated complementary computational analyses that provided structural support for the biological findings. Molecular docking experiments indicated that ANIT forms stable interactions within the inhibitory binding pocket of BSEP, consistent with the idea that the chemical directly interferes with the pump’s function. This structural insight is significant because BSEP inhibition has become a major concern in pharmaceutical development; drug candidates that block the pump are frequently flagged for cholestatic risk, and regulatory agencies and the International Transporter Consortium have emphasized BSEP inhibition testing as a tool for predicting liver injury liability. By anchoring the ANIT model to a structurally plausible mechanism of BSEP interference, the study strengthens the relevance of the selenium protection data to broader questions of drug-induced cholestasis.

Selenium itself is a fascinating and double-edged nutrient. As an essential trace element, it is incorporated into selenoproteins, including the glutathione peroxidases and thioredoxin reductases that form the biochemical backbone of antioxidant defense. Prior research has documented protective effects of selenium against oxidative injury in the kidney, the nervous system, and the liver in various toxicological models, and recent work has linked dietary selenium to amelioration of fatty liver disease through the KEAP1/NRF2 pathway. Yet the element also has a well-defined toxic threshold. The European Food Safety Authority has established a tolerable upper intake level for selenium, and excess intake can itself produce oxidative stress and selenosis. The dose-dependence observed in the current study, in which half the effective dose failed to confer significant protection, underscores that selenium biology is not a simple linear relationship between intake and benefit.

The authors are careful to frame their findings as evidence for a prophylactic rather than a therapeutic role. In the experimental design, selenium was administered before ANIT exposure, meaning the element was present in liver tissue before the cholestatic insult began. This pretreatment strategy allowed selenium to prime antioxidant defenses and stabilize transporter expression ahead of injury, but it does not demonstrate that selenium could reverse established cholestasis. For patients already suffering from cholestatic liver disease, whether from biliary obstruction, drug toxicity, or autoimmune conditions, the study does not yet provide a basis for selenium as a treatment. What it does provide is a proof of principle that maintaining hepatic redox homeostasis and BSEP expression before an insult can dramatically reduce the severity of the resulting injury.

The implications extend in several directions. For clinicians and nutrition scientists, the work adds hepatobiliary protection to the growing list of selenium-dependent health benefits, while reinforcing the importance of adequate but not excessive selenium status. For toxicologists and drug developers, the detailed mapping of the BSEP-FXR-centered protective network offers a mechanistic template for evaluating candidate cholestasis-preventing compounds. And for basic researchers, the study highlights the intricate interplay between bile acid transport, redox signaling, inflammatory pathways, and cell survival machinery that determines whether a stressed liver recovers or spirals into fibrosis. As cholestatic liver diseases continue to impose a substantial clinical burden worldwide, the humble trace element that helps glutathione peroxidase neutralize peroxides may prove to be an unexpectedly powerful ally, provided the dose, the timing, and the therapeutic window are respected with the precision this new research demands.

Subject of Research: Selenium pretreatment and protection against ANIT-induced cholestatic liver injury via BSEP preservation and redox homeostasis

Article Title: Selenium pretreatment alleviates ANIT-induced cholestasis by preserving BSEP expression and hepatic redox homeostasis

Article References: Bolat, İ., Özdemir, S., Çomakli, S., Sağlam, Y. S., Tekin, S., Çinar, B., Bolat, M., Orhan, B., Sağsöz, M. E., & Okkay, U. (2026). Selenium pretreatment alleviates ANIT-induced cholestasis by preserving BSEP expression and hepatic redox homeostasis. Molecular Biology Reports, 53(1), Article 1658. https://doi.org/10.1007/s11033-026-12849-w

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12849-w

Keywords: selenium, cholestasis, BSEP, ANIT, liver injury, oxidative stress, FXR, NRF2, bile acid transporters, NF-kB, hepatoprotection, rats

The review, led by Minho Seo and Jae-Hyeon Lee of Konkuk University together with colleagues under the supervision of Jooho Park, traces the mechanistic foundations that make bile acids such versatile drugs. Their biological effects are mediated largely through a set of dedicated receptors: the nuclear farnesoid X receptor, or FXR, which acts as a master homeostat for hepatic nutrient metabolism, and the cell-surface G-protein-coupled receptor TGR5, also known as GPBAR1, which links bile acid sensing to energy expenditure and immune tone. Activation of TGR5 in enteroendocrine cells promotes glucagon-like peptide-1 secretion, a pathway of intense interest for diabetes and obesity, while FXR signaling suppresses bile acid synthesis and orchestrates the enterohepatic feedback loop that keeps the bile acid pool in check. Additional receptors, including the pregnane X receptor, the constitutive androstane receptor, the vitamin D receptor, and the sphingosine-1-phosphate receptor 2, broaden the signaling repertoire considerably.

Structural biology has sharpened these targets considerably in recent years. High-resolution structures of the bile acid transporter NTCP, which doubles as the receptor for hepatitis B and D viruses, and of the apical sodium-dependent bile acid transporter, ASBT, have revealed the molecular details of how bile acids are shuttled across membranes. Crystallographic snapshots of GPBAR activation have likewise clarified how subtle differences in the steroidal scaffold translate into receptor selectivity. This structural knowledge underpins the design of transporter-targeted delivery systems, in which bile acid motifs are grafted onto drugs to hijack the body’s own recycling machinery, allowing orally administered molecules, including large peptides, to cross the intestinal epithelium through transporter-mediated endocytosis.

The clinical track record of bile acid therapeutics is already substantial. Ursodeoxycholic acid has been a mainstay for cholestatic liver disease for decades, and its semisynthetic relatives, including norursodeoxycholic acid, have shown anticholestatic and anti-inflammatory effects in models of sclerosing cholangitis and fatty liver disease. Obeticholic acid, a potent semisynthetic FXR agonist derived from chenodeoxycholic acid, demonstrated significant improvements in patients with primary biliary cholangitis in a placebo-controlled trial and has been evaluated extensively in non-alcoholic steatohepatitis, now termed metabolic dysfunction-associated steatohepatitis, or MASH. Phase 2 and phase 3 studies of obeticholic acid in fibrotic NASH showed reductions in hepatic injury markers, even as the community continues to weigh long-term safety and lipid effects.

Alongside these steroidal agonists, a wave of non-bile acid FXR modulators has entered the clinic. Tropifexor, a highly potent non-bile acid agonist, was well tolerated in healthy volunteers and abrogated steatohepatitis and fibrosis in rodent models through an antioxidative gene expression profile. EDP-305, another non-bile acid agonist, potently suppressed liver injury and fibrosis in preclinical studies and advanced into a phase 2 dose-ranging trial in NASH patients, while MET409, a structurally optimized FXR agonist, reduced liver fat content over twelve weeks in patients. Dual agonists such as INT-767, which activates both FXR and TGR5, and BAR502, which promotes browning of white adipose tissue while reversing liver steatosis and fibrosis, illustrate the trend toward multi-receptor engagement. The review emphasizes that improving receptor selectivity and tissue specificity remains the central medicinal chemistry challenge in this field.

Cholestatic disease has also been transformed by a different class of bile acid-directed drugs: the ileal bile acid transporter inhibitors. By blocking ASBT-mediated reabsorption in the terminal ileum, agents such as odevixibat, maralixibat, and linerixibat increase fecal bile acid excretion and reduce the toxic pool circulating in cholestatic liver. Odevixibat has shown benefit in phase 3 trials of progressive familial intrahepatic cholestasis and received regulatory approval for associated pruritus, while maralixibat demonstrated efficacy in Alagille syndrome and in a multicenter phase 3 trial of progressive familial intrahepatic cholestasis. Norursodeoxycholic acid improved cholestasis in primary sclerosing cholangitis, and recent work characterizing the carrier cross-reactivity profiles of these inhibitors is helping clinicians match the right molecule to the right patient population.

Perhaps the most visually striking frontier described in the review is the use of bile acids as building blocks for drug delivery. Their facial amphiphilicity, one hydrophobic face and one hydrophilic face on the same rigid steroid, makes them superb self-assembling units. Researchers have exploited this to create drug conjugates, polymeric carriers, peptide-based platforms, and nanostructured delivery systems. Cholic acid-conjugated oxaliplatin has been developed as a liver-targeted prodrug, glycocholic acid-modified micelles have enabled oral delivery of gemcitabine, and ursodeoxycholic acid-based molecular blocks respond to the acidic tumor microenvironment. Catechol-modified bile acid conjugates have been engineered into pH-responsive nanoparticles that exploit ASBT for intestinal uptake, and charge-based supramolecular peptide nanocomplexes have been designed for oral delivery via transporter-driven endocytosis, a strategy relevant to biologics such as semaglutide and liraglutide.

Bile acid chemistry is even reaching into oncology and immunotherapy. Ursodeoxycholic acid platinum(IV) conjugates have been reported as antiproliferative and antimetastatic agents that remodel the tumor microenvironment by suppressing JAK2/STAT3 signaling. Self-assembled nanocrystals combining obeticholic acid with atorvastatin accumulate in the liver and potentiate treatment of metabolic-associated fatty liver disease. Bile acid-containing lipid nanoparticles have been shown to enhance extrahepatic mRNA delivery, an intriguing twist for the mRNA medicine field, while facially amphiphilic bile acid-functionalized antimicrobials combat pathogenic bacteria, fungi, and their biofilms. Bone tissue engineering based on bile acid scaffolds rounds out a materials portfolio that extends far beyond the gut and liver.

The review also situates bile acids within the ecology of the gut microbiome, an area that has exploded in the past decade. Microbial enzymes, including bile salt hydrolases that catalyze the formation of amine-conjugated bile acids, dramatically expand the chemical diversity of the bile acid pool, and microbiome-driven dehydroxylation pathways generate species with distinct receptor activities. Because microbial bile acid modulation shapes host metabolism, immunity, and digestive health, the authors note that future therapeutics may need to be designed with the microbiome in mind, either by resisting microbial transformation or by deliberately harnessing it. This systems-level perspective reinforces the idea that bile acids function less like simple detergents and more like a distributed endocrine signaling network.

Looking ahead, the authors argue that continued innovation in receptor-selective derivatives and transporter-targeted delivery systems should accelerate clinical translation, particularly for hepatobiliary, metabolic, and oncological diseases. The outstanding barriers are familiar ones: oral bioavailability for large conjugates, tissue-specific targeting that avoids off-target receptor activation, and long-term clinical safety, especially for chronic metabolic indications. With the structural biology of transporters and receptors now largely solved, and with biomaterial engineering supplying an expanding toolbox of conjugates and nanocarriers, the field appears positioned to convert a century-old physiological curiosity into a next-generation therapeutic platform, one rigid steroidal scaffold at a time.

Subject of Research: Bile acid-based therapeutics, including semisynthetic derivatives, receptor agonists, and bile acid-inspired drug delivery systems

Article Title: Bile acid-based therapeutics: recent advances in bile acid conjugates and derivatives

Article References: Seo, M., Lee, J.-H., Yang, S.-B., Ma, G., Lee, H., Han, J., Ryu, Y., & Park, J. (2026). Bile acid-based therapeutics: recent advances in bile acid conjugates and derivatives. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00830-5

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00830-5

Keywords: bile acids, FXR agonists, TGR5, bile acid transporters, obeticholic acid, cholestasis, MASH, drug delivery, nanoparticles, gut microbiome, drug conjugates, pharmaceutical research